Tadbelt n wučči d isafaren

Tadbelt n wučči d isafaren
	;
Isefka
Isem amaddud	Food and Drug Administration
Isem asgezlan	FDA
Anaw	agence fédérale des États-Unis (fr) d organisation de sécurité alimentaire (fr)
Tamurt	Iwunak Yeddukklen n Temrikt
Armud
Agmam deg	ORCID
Amur seg	département de la Santé et des Services sociaux des États-Unis (fr)
Analam	Center for Biologics Evaluation and Research (en) , Center for Devices and Radiological Health (en) , Center for Drug Evaluation and Research (en) , Center for Food Safety and Applied Nutrition (en) , Center for Veterinary Medicine (en) , National Center for Toxicological Research (en) d Center for Tobacco Products (en)
Nombre d’employés (fr)	17 468 (2018)
Langue utilisée (fr)	Taglizit
Tinnebṭit
Aselway	Janet Woodcock (fr)
Asutel amatu	White Oak (fr)
Imlan	département de la Santé et des Services sociaux des États-Unis (fr)
Propriétaire de (fr)	IPLEDGE (fr)
Financial data
Budget (fr)	6 500 000 000 $ (2022)
Amezruy
Asnulfu	30 Yunyu 1906
Asebdad	Harvey Washington Wiley (fr)
	fda.gov ;

Tadbelt n wučči d isafaren (S Tegnizit: Food and Drug Administration - s usegzel: FDA neɣ USFDA) d tanegga yeṭṭafaren aɣlif n Iwunak Yeddukklen n Temrikt i yimeẓla n tdawsa d izerfan n wemdan. Akken i tga d yiwet gar tdeblin tiselkamin tifidiṛalyin deg Marikan.^[1]^[2]^[3] Tadbelt n wučči d isafaren i d (tamasayt) ɣef taggaẓt d usnerni n tdawsa tamatut s ferru d waggal (asefqed) ɣef tɣellist n wučči d ifarisen n ubaɣa d tsutay d isafaren d yicraṭen d tnegwa tisnudranin d temhalin n tufkit n idammen d tinezririn

Asadaf n wučči d isafaren d tnezririn

Ẓeṛ daɣen

↑ Ridley DB, Grabowski HG, Moe JL (2006). "Developing drugs for developing countries". Health Aff (Millwood). 25 (2): 313–24. doi:10.1377/hlthaff.25.2.313. PMID 16522573. Unknown parameter |akala n ufaylu= ignored (help); Unknown parameter |azmez n ufaylu= ignored (help)
↑ MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Accessed October 9, 2007 Archived 2018-01-03 at the Wayback Machine
↑ Nelson, LS; Loh, M; Perrone, J (June 2014). "Assuring safety of inherently unsafe medications: the FDA risk evaluation and mitigation strategies". Journal of medical toxicology : official journal of the American College of Medical Toxicology. 10 (2): 165–72. doi:10.1007/s13181-013-0374-z. PMC 4057549. PMID 24414251.

[1] Ridley DB, Grabowski HG, Moe JL (2006). "Developing drugs for developing countries". Health Aff (Millwood). 25 (2): 313–24. doi:10.1377/hlthaff.25.2.313. PMID 16522573. Unknown parameter |akala n ufaylu= ignored (help); Unknown parameter |azmez n ufaylu= ignored (help)

[2] MedWatch: The FDA Safety Information and Adverse Event Reporting Program. Accessed October 9, 2007 Archived 2018-01-03 at the Wayback Machine

[3] Nelson, LS; Loh, M; Perrone, J (June 2014). "Assuring safety of inherently unsafe medications: the FDA risk evaluation and mitigation strategies". Journal of medical toxicology : official journal of the American College of Medical Toxicology. 10 (2): 165–72. doi:10.1007/s13181-013-0374-z. PMC 4057549. PMID 24414251.

[1]

[2]

[3]